Galmed Pharmaceuticals Ltd.
GLMD
$1.55
-$0.08-4.91%
NASDAQ
| 03/31/2025 | 06/30/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.60% | 12.24% | 12.24% | 36.76% | 36.76% |
| Total Depreciation and Amortization | -- | 722.22% | 722.22% | 50.00% | 50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.73% | -22.08% | -22.08% | 29.41% | 29.41% |
| Change in Net Operating Assets | 75.98% | 87.19% | 87.19% | -172.31% | -172.31% |
| Cash from Operations | 40.73% | 44.43% | 44.43% | -103.79% | -103.79% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 93.49% | 222.22% | 222.22% | -81.04% | -81.04% |
| Cash from Investing | 93.49% | 222.22% | 222.22% | -81.04% | -81.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 237.95% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 237.95% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.29% | 126.82% | 126.82% | -201.23% | -201.23% |